Catalog No.
PAC90702
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Rituximab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Rituxan.
Specificity
The product is specific for Rituximab. This antibody serves as an excellent positive control for Rituximab immunogenicity (ADA) assays.
Concentration
0.5 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 174722-31-7
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Rituximab (Rituxan) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with certain autoimmune diseases and types of cancer, such as non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, idiopathic thrombocytopenic purpura, and pemphigus vulgaris. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death.
Clinical and Electrodiagnostic Findings in Anti-myelin-Associated Glycoprotein Antibody Polyneuropathy: A Single Center Review., PMID:40513035
Emerging Role of Targeted Monoclonal Antibodies in Neuromyelitis Optica Spectrum Disorders., PMID:40506618
Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA., PMID:40506105
FcRn inhibitors in immune thrombocytopenia: A comprehensive review of therapeutic advances and clinical outcomes., PMID:40505332
A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD., PMID:40504994
Clinical uptake of an antigen-based approach to membranous nephropathy: a survey of general nephrologists and glomerular disease experts., PMID:40500560
Combination therapy of rituximab and mycophenolate in patients with systemic sclerosis and primary cardiac involvement refractory to cyclophosphamide: a retrospective exploratory analysis of 10 cases., PMID:40499976
Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601
Economic Evaluation of Rituximab Versus Corticosteroid-Cyclophosphamide or Cyclosporine in Patients With Membranous Nephropathy in Republic of Korea., PMID:40492539
Rituximab as First-Line Compared to Escalation Immunotherapy Is Associated With Lower Disability Accumulation in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Multicenter Cohort Study From Germany and the United Kingdom., PMID:40492480
Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report., PMID:40491913
Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment., PMID:40488894
Advances and challenges in leukemia treatment: A focus on monoclonal antibodies and emerging therapies., PMID:40486885
Dual Autoimmunity: A Case Report of the Sequential Development of Systemic Lupus Erythematosus in a Patient With Anti-MDA5 Dermatomyositis., PMID:40486387
Treatment of Nephrotic Syndrome With Antinephrin Antibodies Using Plasmapheresis, Rituximab, and Mycophenolate Mofetil., PMID:40485695
What Is the Evidence on Immunomodulators and Immunosuppressants for Progressive Multiple Sclerosis? - A Cochrane Review Summary with Commentary., PMID:40485316
[Diagnosis, treatment, and genetic analysis of five cases of primary atypical hemolytic uremic syndrome]., PMID:40484823
Complex presentation of probable catastrophic antiphospholipid syndrome: diagnostic dilemmas and treatment strategies., PMID:40484440
Role of Chimeric Antigen Receptor-Expressing Cell Therapy in Immune-Mediated Kidney Diseases: A Review., PMID:40484342
Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab., PMID:40480240
The TMA team and TTP pathway improved outcomes in a cohort with Thrombotic thrombocytopenic purpura., PMID:40478853
The Use of Biologics for Thyroid Eye Disease., PMID:40478400
Preclinical evaluation of glycan-targeting monoclonal antibodies for bimodal near-infrared fluorescence and photoacoustic imaging of gastrointestinal cancers., PMID:40478321
A case report of Isaacs' syndrome with treatment-resistant pain responsive to rituximab., PMID:40476450
Clinical outcomes of newly diagnosed PCNSL treated with rituximab-methotrexate-cytarabine with or without ibrutinib: a retrospective study., PMID:40475774
Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022., PMID:40473981
Advances in the treatment of ANCA-associated vasculitis., PMID:40473820
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia., PMID:40472329
[Severe late-onset neutropenia after rituximab administration]., PMID:40467890
[Diffuse large B-cell lymphoma presenting with anti-MAG/SGPG IgM gammopathy and neurolymphomatosis at onset]., PMID:40467458
Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma., PMID:40467383
Sarcopenia attenuates the efficacy of PEGylated granulocyte colony-stimulating factor in preventing febrile neutropenia., PMID:40464791
Translational insights from EAE models : decoding MOGAD pathogenesis and therapeutic innovation., PMID:40463369
MOGAD treatment outcomes and relapse characteristics: Real world experience from a Low-Middle income country., PMID:40460615
Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review., PMID:40460386
Autoantibodies as prognostic markers in rheumatoid arthritis., PMID:40458132
Successful treatment of refractory erythrodermic pemphigus foliaceus with low-dose rituximab and intravenous immunoglobulin., PMID:40457086
Severe Worsening of Neuropathy Associated With Antibodies Against Myelin-Associated Glycoprotein by Rituximab Resembling Chronic Inflammatory Demyelinating Polyneuropathy., PMID:40452709
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284
Aging in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: From Pathophysiology to Clinical Management., PMID:40448791
Granulomatosis with Polyangiitis Presenting as Pancreatic Pseudotumor and Peripancreatic Lymphadenitis: Diagnostic Challenges and Review of 55 Cases., PMID:40448314
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis: A Multicenter Cohort Study., PMID:40446185
Hemolytic uremic syndrome in severe acute pancreatitis., PMID:40443860
Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis., PMID:40443484
Efficacy and Safety of Rituximab in Connective Tissue Disease-Associated Thrombotic Thrombocytopenic Purpura/Thrombotic Microangiopathy., PMID:40442995
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445
Antibody-mediated Rejection - Treatment Standard., PMID:40440205
Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review., PMID:40438359
MPO-ANCA-Associated Hypertrophic Pachymeningitis Mimicking IgG4-Related Disease: A Case Report and Literature Review., PMID:40438183
Treating newly diagnosed Diffuse Large B-cell Lymphoma in the elderly patient with R-mini-CHOP: A single centre analytical retrospective observational study., PMID:40437719
For research use only. Not for human or drug use.
